Press releases
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
- Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
- Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.85 |
---|---|
High | 29.85 |
Low | 29.85 |
Bid | 31.10 |
Offer | 31.50 |
Previous close | 30.25 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.60m |
Free float | 31.99m |
P/E (TTM) | -- |
Market cap | 1.19bn USD |
EPS (TTM) | -75.04 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:04 BST.
More ▼